This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Spread and adoption of supported innovations

The Innovation Exchange supports the adoption of innovations identified by the Accelerated Access Collaborative as well as identifying and supporting the adoption of innovations on a regional and cross-regional basis.

Accelerated Access Collaborative

The Accelerated Access Collaborative (AAC) aims to make the process of getting transformative technologies to patients quicker, cheaper and easier for innovators and the NHS.

The government and its partners, including the Oxford AHSN, aim to bring forward patient access to selected, highly beneficial and affordable innovations.

The AAC is currently supporting the rapid uptake of seven high-potential technology areas with full evidence bases which are already available within the health and care system. These AAC rapid uptake products will enable patients with conditions such as cancer, heart disease and multiple sclerosis to access new treatments faster.

The seven products are:

  • Heartflow – A non-invasive personalised cardiac test that reduces the need for unnecessary procedures
  • Placental growth factor (PlGF) based testing for suspected pre-eclampsia – tests for early diagnosis of pre-eclampsia in pregnant women which, if unmonitored, can cause serious complications for mother and baby. Two tests are available
  • PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia – Two cost-effective drugs that significantly lower cholesterol.
  • High sensitivity troponin tests for early rule-out of myocardial infarction (acute) – two diagnostic tests are available that detect whether or not a patient is at risk or previously had a heart attack
  • Quantitative faecal immunochemical tests for colorectal cancer – Diagnostic tests that reduce referrals for patients with suspected colorectal cancer. Three tests are available for adoption
  • Cladribine to treat highly active relapsing-remitting multiple sclerosis in adults – A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden (brand name: Mavenclad)
  • UroLift for lower urinary tract symptoms of benign prostatic hyperplasia.

Innovation and Technology Payment

The Innovation and Technology Payment (ITP) 2019/20 supports NHS England’s commitment to accelerate the adoption and spread of proven and affordable innovations, as set out as part of the Five Year Forward View and NHS Long Term Plan. The ITP aims to remove the financial and procurement barriers to support the NHS adopt innovative medical devices, diagnostics and digital products at scale.

The following themes are supported in 2019/20:

  • Non-invasive vagus nerve stimulation therapy for the treatment of cluster headaches
  • Absorbable spacer to reduce rectum radiation exposure during prostate radiation therapy
  • Placental growth factor (PlGF) based test to rule out pre-eclampsia (see below)
  • High sensitivity troponin assay in a rapid rule out protocol for acute myocardial infarction.

Two further themes, with limited roll-out and more intensive evaluation support, are being supported through the ‘evidence generation fund’:

  • Digital apps to support emergency/crisis mental health assessments
  • Interoperable personal health record tool.

Key projects at the Oxford AHSN: